The latest on leukodystrophies

Current Opinion in Neurology

Volumn 17, Issue 2, 2004, Pages 187-192

  Schiffmann, Raphael ^a   Van Der Knaap, Marjo S ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adrenoleukodystrophy; Eukaryocytic initiation factor; H ABC; LBSL; Leukodystrophy; Proteolipid protein

Indexed keywords

GUANINE NUCLEOTIDE EXCHANGE FACTOR; PROTEOLIPID PROTEIN;

ADRENOLEUKODYSTROPHY; ATAXIA; BASAL GANGLION; BRAIN ATROPHY; BRAIN STEM; CENTRAL NERVOUS SYSTEM DISEASE; CEREBELLUM; CHILDHOOD DISEASE; GENETIC DISORDER; HUMAN; LEUKODYSTROPHY; PATHOGENESIS; REVIEW; SPINAL CORD; WHITE MATTER; X CHROMOSOME LINKED DISORDER;

ADRENOLEUKODYSTROPHY; ADULT; ATROPHY; BRAIN; CHILD; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; ENERGY METABOLISM; EUKARYOTIC INITIATION FACTOR-2B; HEREDITARY CENTRAL NERVOUS SYSTEM DEMYELINATING DISEASES; HUMANS; INFANT; MYELIN PROTEINS; NERVE FIBERS, MYELINATED; PROTEOLIPIDS; SPHINGOLIPIDOSES; SPINAL CORD; SYNDROME;

EID: 1842610164     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200404000-00017     Document Type: Review

References (30)

1. Schiffmann R, Boespflug-Tanguy O. An update on the leukodsytrophies. Curr Opin Neurol 2001; 14:789-794.
2. Leegwater PA, Vermeulen G, Konst AA, et al. Subunits of the translation initiation factor elF2B are mutant in leukoencephalopathy with vanishing white matter. Nat Genet 2001; 29:383-388.
3. van der Knaap MS, Leegwater PA, Konst AA, et al. Mutations in each of the five subunits of translation initiation factor elF2B can cause leukoencephalopathy with vanishing white matter. Ann Neurol 2002; 51:264-270. The authors discovered the full extent of this complex syndrome.
4. Leegwater PA, Pronk JC, van der Knaap MS. Leukoencephalopathy with vanishing white matter: from magnetic resonance imaging pattern to five genes. J Child Neurol 2003; 18:639-645. This is a recent and comprehensive review on this topic.
5. Proud CG. Regulation of mammalian translation factors by nutrients. Eur J Biochem 2002; 269:5338-5349.
6. Proud CG. Regulation of eukaryotic initiation factor elF2B. Prog Mol Subcell Biol 2001; 26:95-114.
7. Fogli A, Wong K, Eymard-Pierre E, et al. Cree leukoencephalopathy and CACH/VWM disease are allelic at the ElF2B5 locus. Ann Neurol 2002; 52:506-510. This first 'non-classic' phenotype of VWM/CACH was suspected initially on the basis of similar abnormalities of oligodendrocytes that are present in the classic form of this syndrome.
8. Wong K, Armstrong RC, Gyure KA, et al. Foamy cells with oligodendroglial phenotype in childhood ataxia with diffuse central nervous system hypomyelination syndrome. Acta Neuropathol (Berl) 2000; 100:635-646.
9. Fogli A, Dionisi-Vici C, Deodato F, et al. A severe variant of childhood ataxia with central hypomyelination/vanishing white matter leukoencephalopathy related to ElF21B5 mutation. Neurology 2002; 59:1966-1968.
10. van der Knaap MS, Barth PG, Gabreels FJ, et al. A new leukoencephalopathy with vanishing white matter. Neurology 1997; 48:845-855.
11. Schiffmann R, Tedeschi G, Kinkel RP, et al. Leukodystrophy in patients with ovarian dysgenesis. Ann Neurol 1997; 41:654-661.
12. Fogli A, Rodriguez D, Eymard-Pierre E, et al. Ovarian failure related to eukaryotic initiation factor 2B mutations. Am J Hum Genet 2003; 72:1544-1550. The elF2B mutations are now among the few single gene defects known to cause ovarian failure.
13. Van Der Knaap MS, Van Berkel CG, Herms J, et al. elF2B-Related disorders: antenatal onset and involvement of multiple organs. Am J Hum Genet 2003; 73:1199-1207. This paper provides further delineation of the extensive VWM/CACH phenotype that now includes the entire life span.
14. Bluml S, Philippart M, Schiffmann R, et al. Membrane phospholipids and high-energy metabolites in childhood ataxia with CNS hypomyelination. Neurology 2003; 61:648-654.
15. van der Knaap MS, Naidu S, Pouwels PJ, et al. New syndrome characterized by hypomyelination with atrophy of the basal ganglia and cerebellum. AJNR Am J Neuroradiol 2002; 23:1466-1474.
16. van der Knaap MS, van der Voorn P, Barkhof F, et al. A new leukoencephalopathy with brainstem and spinal cord involvement and high lactate. Ann Neurol 2003; 53:252-258.
17. Serkov SV, Pronin IN, Bykova OV, et al. Five patients with a recently described novel leukoencephalopathy with brainstem and spinal cord involvement and elevated lactate. Neuropediatrics 2004; (in press).
18. McGuinness MC, Lu JF, Zhang HP, et al. Role of ALDP (ABCD1) and mitochondria in X-linked adrenoleukodystrophy. Mol Cell Biol 2003; 23:744-753.
19. Zhang LX, Bakshi R, Fine E, Moser HW. Clinical and electrophysiological improvement of adrenomyeloneuropathy with steroid treatment. J Neurol Neurosurg Psychiatry 2003; 74:822-823.
20. Loes DJ, Fatemi A, Melhem ER, et al. Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy. Neurology 2003; 61:369-374.
21. Kaye EM, Doll RF, Natowicz MR, Smith FI. Pelizaeus-Merzbacher disease presenting as spinal muscular atrophy: clinical and molecular studies. Ann Neurol 1994; 36:916-919.
22. Garbern JY, Cambi F, Lewis R, et al. Peripheral neuropathy caused by proteolipid protein gene mutations. Ann N Y Acad Sci 1999; 883:351-365.
23. Shy ME, Hobson G, Jain M, et al. Schwann cell expression of PLP1 but not DM20 is necessary to prevent neuropathy. Ann Neurol 2003; 53:354-365. This work represents an important advance in our ability to predict which PLP1 mutations will cause peripheral nerve involvement.
24. Vaurs-Barriere C, Wong K, Weibel TD, et al. Insertion of mutant proteolipid protein results in missorting of myelin proteins. Ann Neurol 2003; 54:769-780. This paper describes a novel mechanism of myelin disruption and provides a direct demonstration of the presence of mutant PLP in the myelin sheath and its consequences regarding other structural proteins, using a combination of immunohistochemistry and immunogold electron microscopy.
25. Southwood CM, Garbern J, Jiang W, Gow A. The unfolded protein response modulates disease severity in Pelizaeus-Merzbacher disease. Neuron 2002; 36:585-596.
26. Al-Saktawi K, McLaughlin M, Klugmann M, et al. Genetic background determines phenotypic severity of the Plp rumpshaker mutation. J Neurosci Res 2003; 72:12-24.
27. Garbern JY, Yool DA, Moore GJ, et al. Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation. Brain 2002; 125:551-561.
28. Lappe-Siefke C, Goebbels S, Gravel M, et al. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat Genet 2003; 33:366-374. This paper describes a surprise finding that indicates that one cannot predict the function of the protein on the basis of its cellular location.
29. Fogli A, Schiffmann R, Bertini E, et al. The effect of genotype on the natural history of elF2B-related leukodystrophies. Neurology; (in press).
30. Van der Knaap MS, Leegwater PAJ, van Berkel CGM, et al. Arg113His mutation in elF2Bepsilon as cause of leukoencephalopathy in adults. Neurology; (in press).